Active substances
Estradiol + Progesterone
- US FDA 2
- Health Canada 1
- US price lines 2
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BIJUVA | 1MG;100MG; 0.5MG;100MG | capsule · oral | MAYNE PHARMA | Prescription | 28 Oct 2018 |
| ESTRADIOL AND PROGESTERONE | 1MG;100MG | capsule · oral | AMNEAL PHARMS | Discontinued | 16 May 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BIJUVA | 02505223 | 100 MG; 1 MG | CAPSULE · ORAL | KNIGHT THERAPEUTICS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BIJUVA 0.5 MG-100 MG CAPSULE | $8.84931 | per EA | 1 Jun 2026 |
| US NADAC | BIJUVA 1 MG-100 MG CAPSULE | $8.53176 | per EA | 1 Jun 2026 |
| NHS Drug Tariff | Estradiol 1mg / Progesterone 100mg capsules | £8.14 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.